title: [Docetaxel in the treatment of advanced breast cancer ].
abstract: OBJECTIVE
  To evaluate the efficacy, toxicity and safety of an new domestic docetaxel in the treatment of pretreated advanced breast cancer.
  
  
  METHODS
  Fourty-four breast cancer patients who had failed in first-line chemotherapy were included in this trial. They received docetaxel as the second-line chemotherapy. Docetaxel was administered alone at a dose of 70 mg/m2 every 3 weeks. The use of granulocyte colony-stimulating factor to prevent granulocytopenia was not permitted. The response rate and toxicity were evaluated by World Health Organization toxicity scale and performance status by Karnofsky scale.
  
  
  RESULTS
  Of the 41 evaluable patients, 4 achieved complete response and 14 partial remission, with a response rate and clinical benefit rate of 43.9% and 85.4%, respectively. Grade 3 or grade 4 neutropenia developed in 42.9%, alopecia in 7.1% and vomiting in 4.8% of these patients. Fluid retention was not observed in this series.
  
  
  CONCLUSIONS
  Three-week administration of docetaxel alone at a dose of 70 mg/m2 is effective and tolerable. It provides an alternative for the pretreated advanced breast cancer patients.
authors.affiliation: Department of Medical Oncology, Cancer Hospital (Institute), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China. pingziwang@yahoo.com
authors.forename: Zi-Ping
authors.initials: ZP
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.forename: Xiang-Ru
authors.initials: XR
authors.lastname: Zhang
authors.forename: Mao-Hong
authors.initials: MH
authors.lastname: Zhang
authors.forename: Xiu-Wen
authors.initials: XW
authors.lastname: Wang
authors.forename: Xue-Jun
authors.initials: XJ
authors.lastname: Yu
authors.forename: Ke-Jun
authors.initials: KJ
authors.lastname: Nan
authors.forename: En-Xiao
authors.initials: EX
authors.lastname: Li
authors.forename: Ji-Wei
authors.initials: JW
authors.lastname: Liu
authors.forename: Ya-Jie
authors.initials: YJ
authors.lastname: Gao
authors.forename: Xiao-Qian
authors.initials: XQ
authors.lastname: Guan
authors.forename: Shu-Ping
authors.initials: SP
authors.lastname: Song
authors.forename: Li-Jun
authors.initials: LJ
authors.lastname: Sheng
authors.forename: Dong-Lin
authors.initials: DL
authors.lastname: Wang
authors.forename: Zhi-Xin
authors.initials: ZX
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D012074:Remission Induction; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel